Zura Bio Limited (ZURA)Healthcare | Biotechnology | Henderson, United States | NasdaqCM
5.15 USD
+0.04
(0.783%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.09 -0.06 (-0.060%) ⇩ (July 13, 2026, 6:12 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:37 a.m. EDT
The investment case here is severely compromised by a deteriorating business trajectory. The company has suffered a catastrophic collapse in shareholder value, dropping nearly 80% over the last two years with two consecutive years of double-digit declines. Fundamentally, the picture is bleak: the company is burning through cash with negative free cash flow, negative operating cash flow, and negative returns on both assets and equity. While the balance sheet currently shows a massive current ratio due to cash reserves, this is typical for early-stage biotechs and masks the reality that the business is not generating its own capital. The recent news of clinical trial progress and leadership changes offers a glimmer of hope for the pipeline, but the stock has already priced in a significant recovery, trading at a discount to its book value despite the lack of earnings. The options market confirms this pessimism, with heavy put buying establishing a defensive floor at $2.50 while call buyers remain scarce. This is a speculative turnaround play with immense risk, not a sound investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.203352 |
| AutoETS | 0.203353 |
| AutoTheta | 0.215233 |
| MSTL | 0.219002 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.428 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 488,635,680 |
| Forward P/E | -10.30 |
| Beta | -0.04 |
| Website | https://zurabio.com |
As of July 11, 2026, 6:37 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is concentrated deep in-the-money at the $2.50 strike across nearly all expirations, acting as a hard floor. Call activity is sparse and mostly centered at the money or slightly out-of-the-money, with significant volume occurring at strikes far below the current price, suggesting traders are betting on a continuation of the downtrend or a crash to test the $2.50 support level.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.9307692 |
| Address1 | 1,489 W. Warm Springs Road |
| Address2 | Suite 110 |
| All Time High | 37.55 |
| All Time Low | 0.97 |
| Ask | 6.23 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 2,316,720 |
| Average Daily Volume3 Month | 1,073,242 |
| Average Volume | 1,073,242 |
| Average Volume10Days | 2,316,720 |
| Beta | -0.035 |
| Bid | 5.0 |
| Bid Size | 1 |
| Book Value | 2.286 |
| City | Henderson |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.15 |
| Current Ratio | 19.328 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.22 |
| Day Low | 4.85 |
| Display Name | Zura Bio |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -81,435,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.191 |
| Enterprise Value | 259,844,304 |
| Eps Current Year | -0.71 |
| Eps Forward | -0.5 |
| Eps Trailing Twelve Months | -1.09 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4942 |
| Fifty Day Average Change | 0.65579987 |
| Fifty Day Average Change Percent | 0.14592138 |
| Fifty Two Week Change Percent | 293.07693 |
| Fifty Two Week High | 7.44 |
| Fifty Two Week High Change | -2.29 |
| Fifty Two Week High Change Percent | -0.3077957 |
| Fifty Two Week Low | 1.26 |
| Fifty Two Week Low Change | 3.89 |
| Fifty Two Week Low Change Percent | 3.0873017 |
| Fifty Two Week Range | 1.26 - 7.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,679,405,400,000 |
| Float Shares | 50,842,774 |
| Forward Eps | -0.5 |
| Forward P E | -10.3 |
| Free Cashflow | -46,890,876 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 40 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.2151 |
| Held Percent Institutions | 0.78558 |
| Implied Shares Outstanding | 94,880,710 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-03-21 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada. |
| Long Name | Zura Bio Limited |
| Market | us_market |
| Market Cap | 488,635,680 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1783060399 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -106,134,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 485,438,298 |
| Number Of Analyst Opinions | 6 |
| Open | 5.08 |
| Operating Cashflow | -72,675,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 702 825 9872 |
| Post Market Change | -0.059999943 |
| Post Market Change Percent | -1.1650474 |
| Post Market Price | 5.09 |
| Post Market Time | 1,783,980,723 |
| Previous Close | 5.11 |
| Price Eps Current Year | -7.2535214 |
| Price Hint | 2 |
| Price To Book | 2.2528434 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.208 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 0.782778 |
| Regular Market Day High | 5.22 |
| Regular Market Day Low | 4.85 |
| Regular Market Day Range | 4.85 - 5.22 |
| Regular Market Open | 5.08 |
| Regular Market Previous Close | 5.11 |
| Regular Market Price | 5.15 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,180,994 |
| Return On Assets | -0.25394 |
| Return On Equity | -0.40962002 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 94,880,710 |
| Shares Percent Shares Out | 0.09729999 |
| Shares Short | 9,242,718 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,219,823 |
| Short Name | Zura Bio Limited |
| Short Percent Of Float | 0.1303 |
| Short Ratio | 5.51 |
| Source Interval | 15 |
| State | NV |
| Symbol | ZURA |
| Target High Price | 26.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 15.66667 |
| Target Median Price | 15.0 |
| Total Cash | 225,594,000 |
| Total Cash Per Share | 2.375 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.84865 |
| Two Hundred Day Average Change | 0.30135012 |
| Two Hundred Day Average Change Percent | 0.062151346 |
| Type Disp | Equity |
| Volume | 1,180,994 |
| Website | https://zurabio.com |
| Zip | 89,014 |